Stock market today: S&P 500 rides Apple-led tech rally to close higher
Cero Therapeutics Holdings, Inc. (NASDAQ:CERO) announced on Monday that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market, according to a statement based on a recent SEC filing.
The company previously disclosed that it received a notice from the Nasdaq Listing Qualifications Department on June 11, 2025, indicating that the closing bid price for its common stock had fallen below the $1.00 per share minimum required under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days, from April 25 through June 9, 2025.
Cero Therapeutics appealed the potential delisting by requesting a hearing before a Nasdaq Hearings Panel, which temporarily stayed the suspension of its securities. On Monday, Nasdaq informed the company that it had regained compliance with the bid price requirement. As a result, the scheduled hearing was canceled and Cero Therapeutics’ common stock will continue to be listed and traded on the Nasdaq Capital Market.
The information was provided in a press release statement included in the company’s SEC Form 8-K filing.
In other recent news, Cero Therapeutics Holdings, Inc. announced significant developments regarding its financial and clinical strategies. The company completed an additional closing of its Series D preferred stock sale, issuing 2,315 shares for gross proceeds of approximately $1,852,000. This follows a previous closing earlier in June, bringing the total gross proceeds from this private placement to over $2.6 million. Additionally, the U.S. Food and Drug Administration granted Orphan Drug Designation to Cero’s lead candidate, CER-1236, for the treatment of acute myeloid leukemia. This designation provides several benefits, including assistance in clinical trial design and potential seven-year marketing exclusivity if approved.
In a strategic move, Cero Therapeutics also announced a one-for-twenty reverse stock split, reducing its outstanding common shares significantly. This action aims to align the company’s stock structure with its strategic goals. Furthermore, D. Boral (OTC:BOALY) Capital upgraded Cero Therapeutics from Hold to Buy, citing confidence in the company’s innovative approach to T cell engineering for solid tumors. The upgrade reflects optimism about Cero’s proprietary platform and its potential impact on treating various cancers. These developments indicate Cero’s active engagement in both financial and clinical advancements as it progresses with its therapeutic programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.